Insider Transactions in Q1 2019 at Pfizer Inc (PFE)
Insider Transaction List (Q1 2019)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2019
|
Rady A Johnson Executive Vice President |
SELL
Open market or private sale
|
Direct |
8,700
-12.7%
|
$356,700
$41.13 P/Share
|
|
Mar 04
2019
|
Sally Susman Executive Vice President |
SELL
Open market or private sale
|
Direct |
72,723
-0.86%
|
$3,127,089
$43.23 P/Share
|
|
Mar 04
2019
|
Ian C Read Executive Chairman |
SELL
Open market or private sale
|
Direct |
580,866
-0.74%
|
$24,977,238
$43.29 P/Share
|
|
Mar 04
2019
|
Dawn Rogers Executive Vice President |
SELL
Open market or private sale
|
Direct |
15,002
-26.03%
|
$630,084
$42.99 P/Share
|
|
Mar 04
2019
|
Mikael Dolsten President R&D |
SELL
Open market or private sale
|
Direct |
49,082
-2.98%
|
$2,110,526
$43.54 P/Share
|
|
Mar 01
2019
|
Mikael Dolsten President R&D |
SELL
Open market or private sale
|
Direct |
100,471
-5.99%
|
$4,320,253
$43.58 P/Share
|
|
Mar 01
2019
|
Mikael Dolsten President R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
106,191
+11.42%
|
$3,291,921
$31.41 P/Share
|
|
Feb 28
2019
|
Lidia Fonseca Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
47,510
+50.0%
|
-
|
|
Feb 28
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,482
+3.11%
|
-
|
|
Feb 27
2019
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
51,770
-8.02%
|
$2,174,340
$42.62 P/Share
|
|
Feb 27
2019
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
64,322
+16.23%
|
$2,058,304
$32.23 P/Share
|
|
Feb 27
2019
|
Albert Bourla Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+26.44%
|
-
|
|
Feb 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
24,635
-6.66%
|
$1,034,670
$42.72 P/Share
|
|
Feb 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
8,017
+5.82%
|
-
|
|
Feb 27
2019
|
Loretta V Cangialosi Sr. Vice President, Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
25,729
+17.45%
|
$823,328
$32.23 P/Share
|
|
Feb 27
2019
|
Frank A Damelio Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
193,784
-10.3%
|
$8,138,928
$42.72 P/Share
|
|
Feb 27
2019
|
Frank A Damelio Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+12.32%
|
-
|
|
Feb 27
2019
|
Frank A Damelio Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
182,247
+23.66%
|
$5,831,904
$32.23 P/Share
|
|
Feb 27
2019
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
73,773
-9.49%
|
$3,098,466
$42.93 P/Share
|
|
Feb 27
2019
|
Mikael Dolsten President R&D |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+19.14%
|
-
|
|
Feb 27
2019
|
Michael Goettler Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
28,083
-19.49%
|
$1,179,486
$42.72 P/Share
|
|
Feb 27
2019
|
Michael Goettler Group President |
BUY
Grant, award, or other acquisition
|
Direct |
6,680
+10.77%
|
-
|
|
Feb 27
2019
|
Michael Goettler Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,017
+38.16%
|
$960,544
$32.23 P/Share
|
|
Feb 27
2019
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
11,085
-13.47%
|
$465,570
$42.72 P/Share
|
|
Feb 27
2019
|
Angela Hwang President, Global Biopharma |
BUY
Grant, award, or other acquisition
|
Direct |
6,680
+18.06%
|
-
|
|
Feb 27
2019
|
Angela Hwang President, Global Biopharma |
BUY
Exercise of conversion of derivative security
|
Direct |
11,792
+33.29%
|
$377,344
$32.23 P/Share
|
|
Feb 27
2019
|
Rady A Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
35,020
-12.61%
|
$1,470,840
$42.72 P/Share
|
|
Feb 27
2019
|
Rady A Johnson Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
22,176
+17.64%
|
-
|
|
Feb 27
2019
|
Rady A Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,017
+26.96%
|
$960,544
$32.23 P/Share
|
|
Feb 27
2019
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
80,554
-17.24%
|
$3,383,268
$42.72 P/Share
|
|
Feb 27
2019
|
Douglas M Lankler Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
58,778
+24.42%
|
-
|
|
Feb 27
2019
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
64,322
+34.31%
|
$2,058,304
$32.23 P/Share
|
|
Feb 27
2019
|
Freda C Lewis Hall Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
89,126
-6.78%
|
$3,743,292
$42.72 P/Share
|
|
Feb 27
2019
|
Freda C Lewis Hall Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
48,092
+9.38%
|
-
|
|
Feb 27
2019
|
Freda C Lewis Hall Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
81,475
+16.37%
|
$2,607,200
$32.23 P/Share
|
|
Feb 27
2019
|
Alexander R Mackenzie Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
10,882
-8.0%
|
$457,044
$42.93 P/Share
|
|
Feb 27
2019
|
Alexander R Mackenzie Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
20,446
+13.07%
|
-
|
|
Feb 27
2019
|
Dawn Rogers Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
15,127
-15.95%
|
$635,334
$42.62 P/Share
|
|
Feb 27
2019
|
Dawn Rogers Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
4,943
+9.0%
|
-
|
|
Feb 27
2019
|
Dawn Rogers Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
19,297
+29.99%
|
$617,504
$32.23 P/Share
|
|
Feb 27
2019
|
Ian C Read Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
243,996
-6.5%
|
$10,247,832
$42.93 P/Share
|
|
Feb 27
2019
|
Ian C Read Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
347,327
+15.22%
|
-
|
|
Feb 27
2019
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
96,016
-12.94%
|
$4,032,672
$42.72 P/Share
|
|
Feb 27
2019
|
Sally Susman Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
48,092
+14.8%
|
-
|
|
Feb 27
2019
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
85,763
+27.27%
|
$2,744,416
$32.23 P/Share
|
|
Feb 27
2019
|
John D Young Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
171,349
-11.75%
|
$7,196,658
$42.72 P/Share
|
|
Feb 27
2019
|
John D Young Group President |
BUY
Grant, award, or other acquisition
|
Direct |
96,183
+15.16%
|
-
|
|
Feb 27
2019
|
John D Young Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
154,374
+25.89%
|
$4,939,968
$32.23 P/Share
|
|
Feb 25
2019
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
1,565
-11.67%
|
$67,295
$43.08 P/Share
|
|
Feb 25
2019
|
Alexander R Mackenzie Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,759
-2.33%
|
$118,637
$43.08 P/Share
|